NCT02967887 - Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

October 31, 2018

Study Completion Date

December 31, 2018

Conditions

Hepatocellular Carcinoma Non-Resectable

Interventions

DRUG

cisplatin and 5-fluorouracil

Hepatic arterial infusion of Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system (chemoport)

Trial Locations (12)

Unknown

NOT_YET_RECRUITING

Korea University Ansan Hospital, Ansan

NOT_YET_RECRUITING

Sooncheonhyang University Hospital Bucheon, Bucheon-si

NOT_YET_RECRUITING

The Catholic University of Korea Bucheon ST. Mary's Hospital, Bucheon-si

NOT_YET_RECRUITING

Keimyung University Dongsan Medical Center, Daegu

NOT_YET_RECRUITING

The Catholic University of Korea Daejeon ST. Mary's Hospital, Daejeon

NOT_YET_RECRUITING

Chonnam National University Hwasun Hospital, Hwasun

NOT_YET_RECRUITING

Korea University Anam Hospital, Seoul

NOT_YET_RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Sooncheonhyang University Hospital Seoul, Seoul

RECRUITING

The Catholic University of korea, Seoul ST. Mary's Hospital, Seoul

RECRUITING

Ajou University Hospital, Suwon

NOT_YET_RECRUITING

The Catholic University of Korea ST. Vincent's Hospital, Suwon